Pharma News - Chemdiv

Gilead tries again with twice-yearly HIV drug lenacapavir

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February. ...

Ipsen Acquires Epizyme in Initial Deal Worth $247 Million

Ipsen is expanding its cancer drug portfolio with the purchase of Epizyme for $247 million, gaining access to the company’s chemotherapy-free EZH2 inhibitor, Tazverik (tazemetostat). ...

GSK’s Hepatitis Drug Candidate Shows Promise

In interim results from a mid-stage study, GlaxoSmithKline’s hepatitis drug candidate bepirovirsen showed the potential to suppress both the surface antigen and the virus of hepatitis B after 24 ...

BioMarin gene therapy for haemophilia on course for EU approval

The EMA’s human medicines advisory committee has recommended that BioMarin Pharmaceutical’s haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to laun...

Most Women Unaware of Alzheimer’s Risk, Survey Finds

Women in the United States are largely uninformed when it comes to some critical health issues, including their relatively higher risk of developing Alzheimer’s disease as compared to men, accord...

Federal Judge Lets Stand $6.4 Billion Suit Claiming BMS Stalled New CAR T Cell Therapy

A federal judge is letting stand a $6.4 billion claim that Bristol Myers Squibb stalled its CAR T cell therapy Breyanzi (lisocabtagene maraleucel) from getting to the market in order to duck out of...

US FDA accepts Emergent BioSolutions’ BLA for AV7909 anthrax vaccine candidate

Emergent BioSolutions Inc. announced that the US Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).&nb...

Researchers find oral antiviral drug that could provide an effective treatment against respiratory syncytial virus

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could pro...

Otsuka, Lundbeck Tout Positive Phase III Results for Alzheimer's Drug

Otsuka Pharmaceutical and Lundbeck announced positive Phase III clinical trial results Monday regarding brexpiprazole (Rexulti) as a treatment for agitation in patients with Alzheimer’s dementia...

World Health Organization says monkeypox is not a global health emergency right now

The World Health Organization on Saturday said the rapid spread of monkeypox across dozens of nations does not represent a global health emergency at this time. ...

Galapagos Acquires CellPoint and AboundBio for Over $250 Million

Galapagos has inked purchase deals with two biotech companies, CellPoint and AboundBio, aimed at developing chimeric antigen receptor (CAR)-T therapies.

NICE Rejects Fampyra for Multiple Sclerosis

The UK’s National Institute for Health and Care Excellence (NICE) has declined to recommend Acorda Therapeutics’ multiple sclerosis drug Fampyra (fampridine) for National Health Service (NHS) ...